Registry of Endocrine Tumors (Thyroid, Parathyroid, Adrenal, Endocrine Pancreas, Endocrine Digestive Tube)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Endocrine Tumor. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Registre Tumeurs Endocrine - Eurocrine
Overview
This registry aims to collect informations about patients with endocrine tumors (Thyroid, Parathyroid, Adrenal, Endocrine Pancreas, Endocrine Digestive Tube) who undergo endocrine surgical procedures. This registry is part of the Eurocrine Project.
Detailed description
The EUROCRINE project aims to decrease morbidity and mortality of rare endocrine tumours, by means of a pan-European database. Recording and accessing data at the European level, makes it possible to identify these tumours, which cannot be distinguished at local or national level, because of their extreme rarity. Dissemination of results aims to raise clinical standards and reduce differences in practise between clinics and member states, and thereby diminish morbidity and mortality. Comparison of practice and outcomes will be especially interesting for centres wanting to improve their standards to what is currently considered best practice. EUROCRINE will be a key means by which the medical profession, researchers, health policy makers, and not least patients, can benefit from an increase in knowledge related to diagnosis, treatment, and future clinical research in the field of rare endocrine tumours.
Primary outcome measures
- Postoperative complications (endocrine surgical procedure) [Time frame: 12 months after surgical procedure]
Secondary outcome measures (12)
- Postoperative complications severity (endocrine surgical procedure) [Time frame: 12 months after surgical procedure]
- Postoperative mortality (endocrine surgical procedure) [Time frame: 12 months after surgical procedure]
- CT imaging before endocrine surgical procedure (Tumor characteristics) [Time frame: Baseline]
- CT imaging before endocrine surgical procedure (Coronary artery score) [Time frame: Baseline]
- CT imaging before endocrine surgical procedure (Sarcopenia) [Time frame: preoperative period]
- Bone mineral density [Time frame: Baseline]
- Intraoperative systolic arterial pressure [Time frame: Intraoperative]
- Intraoperative diastolic arterial pressure [Time frame: Intraoperative]
- Parathormone plasma levels [Time frame: Baseline and up to 12 months after surgical procedure]
- Aldosterone plasma levels [Time frame: Baseline and up to 12 months after surgical procedure]
- Plasma renin activity [Time frame: Baseline and up to 12 months after surgical procedure]
- Plasma free metanephrines [Time frame: Baseline and up to 12 months after surgical procedure]
Eligibility criteria
Inclusion criteria
- patients who undergo surgical procedures for endocrine tumors at the University Nancy Brabois Hospital
Exclusion criteria
- unable to receive clear information
- refusal to sign the consent form
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
France · 1 center
- CHU Nancy — Vandœuvre-lès-Nancy
Publications
- Greilsamer T, Nomine-Criqui C, Thy M, Ullmann T, Zarnegar R, Bresler L, Brunaud L. Robotic-assisted unilateral adrenalectomy: risk factors for perioperative complications in 303 consecutive patients. Surg Endosc. 2019 Mar;33(3):802-810. doi: 10.1007/s00464-018-6346-2. Epub 2018 Jul 11. PMID 29998394
Identifiers
NCT: NCT03410394 · N° CCTIRS :15.291 Version N°3